Total Valuation
Immunotech Laboratories has a market cap or net worth of $114.99K. The enterprise value is ―.
Market Cap$114.99K
Enterprise Value―
Share Statistics
Immunotech Laboratories has 574,965,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding574,965,000
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Immunotech Laboratories’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.
Return on Equity (ROE)―
Return on Assets (ROA)―
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)―
Revenue Per Employee0.00
Profits Per Employee-123.26K
Employee Count4
Asset Turnover―
Inventory Turnover―
Valuation Ratios
The current PE Ratio of Immunotech Laboratories is ―. Immunotech Laboratories’s PEG ratio is ―.
PE Ratio―
PS Ratio0.00
PB Ratio0.00
Price to Fair Value―
Price to FCF0.00
Price to Operating Cash Flow―
PEG Ratio―
Income Statement
In the last 12 months, Immunotech Laboratories had revenue of 0.00 and earned -493.03K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit-305.55K
Operating Income-470.36K
Pretax Income-493.03K
Net Income-493.03K
EBITDA-454.01K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was ― and capital expenditures ―, giving a free cash flow of ― billion.
Operating Cash Flow―
Free Cash Flow―
Free Cash Flow per Share―
Dividends & Yields
Immunotech Laboratories pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.16
52-Week Price Change―
50-Day Moving Average0.04
200-Day Moving Average―
Relative Strength Index (RSI)100.00
Average Volume (3m)―
Important Dates
Immunotech Laboratories upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
Immunotech Laboratories as a current ratio of ―, with Debt / Equity ratio of ―
Current Ratio―
Quick Ratio―
Debt to Market Cap―
Net Debt to EBITDA―
Interest Coverage Ratio―
Taxes
In the past 12 months, Immunotech Laboratories has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate―
Enterprise Valuation
Immunotech Laboratories EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.
EV to Sales―
EV to EBITDA―
EV to Free Cash Flow―
EV to Operating Cash Flow―
Balance Sheet
Immunotech Laboratories has ― in cash and marketable securities with ― in debt, giving a net cash position of ― billion.
Cash & Marketable Securities―
Total Debt―
Net Cash―
Net Cash Per Share―
Tangible Book Value Per Share―
Margins
Gross margin is ―, with operating margin of ―, and net profit margin of ―.
Gross Margin―
Operating Margin―
Pretax Margin―
Net Profit Margin―
EBITDA Margin―
EBIT Margin―
Analyst Forecast
The average price target for Immunotech Laboratories is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―